Crossmark

Dual inhibition of <scp>AKT</scp> ‐m <scp>TOR</scp> and <scp>AR</scp> signaling by targeting <scp>HDAC</scp> 3 in <i> <scp>PTEN</scp> </i> ‐ or <i> <scp>SPOP</scp> </i> ‐mutated prostate cancer

Crossref DOI link: https://doi.org/10.15252/emmm.201708478

Published Online: 2018-03-09

Published Print: 2018-04

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Yan, Yuqian

An, Jian

Yang, Yinhui

Wu, Di

Bai, Yang

Cao, William

Ma, Linlin

Chen, Junhui

Yu, Zhendong

He, Yundong

Jin, Xin

Pan, Yunqian

Ma, Tao

Wang, Shangqian

Hou, Xiaonan

Weroha, Saravut John

Karnes, R Jeffrey

Zhang, Jun

Westendorf, Jennifer J

Wang, Liguo

Chen, Yu

Xu, Wanhai

Zhu, Runzhi https://orcid.org/0000-0002-9565-7261
Wang, Dejie https://orcid.org/0000-0003-3870-2385
Huang, Haojie https://orcid.org/0000-0003-2751-6413
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (31560320)

Foundation for the National Institutes of Health (CA134514)

National Institutes of Health (CA130908)

National Institutes of Health (CA193239)

U.S. Department of Defense (W81XWH‐14‐1‐0486)
License Information

Accepted Manuscript valid from 2018-03-09

Version of Record valid from 2018-03-09
More Information

Publication History

Received: 2017-09-11

Accepted: 2018-02-08

Published: 2018-03-09

Document is current

Any future updates will be listed below